BiVACOR's Total Artificial Heart Receives FDA Breakthrough Device Designation
BiVACOR, a clinical-stage medical device company developing the world's first titanium Total Artificial Heart (TAH), today announced that its device has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA).
The designation supports the BiVACOR TAH as a bridge to transplant (BTT) for adults with severe biventricular or univentricular heart failure where current treatments, including LVADs, are not viable. The FDA's Breakthrough Device program is reserved for technologies that may significantly improve outcomes for patients with life-threatening or irreversibly debilitating conditions. It offers priority regulatory interaction and accelerated pathways to approval.
'This is more than a regulatory milestone. It's a validation of a concept we've spent decades proving that a fully implantable, total artificial heart isn't just possible, it's necessary,' said Daniel Timms, PhD, Founder and Chief Technology Officer of BiVACOR. 'Patients with biventricular failure have been overlooked for too long. The early results from our clinical trial show that we can give them a second chance, without the compromises of older technologies. The Breakthrough Device Designation puts us on a faster track to deliver exactly that.'
The milestone follows the first phase of BiVACOR's FDA Early Feasibility Study, where five patients in the U.S. received the TAH between July and November 2024. Based on positive safety and performance data, the FDA approved the expansion of the trial to include 15 additional patients starting later this year.
BiVACOR's device represents a new category in artificial heart technology. Compact enough to fit most men and women, the TAH uses magnetic levitation, similar to maglev trains, to suspend a single dual-sided rotor. This rotor simultaneously powers the right and left circulatory systems, mimicking the natural heartbeat without valves or mechanical wear points. Its simplified design allows for pulsatile flow, large blood gaps to reduce trauma, and long-term durability.
'We've seen every kind of artificial heart technology over the last four decades, but this is the first system I've encountered that combines engineering elegance, efficiency, and safety with true clinical viability,' said William Cohn, MD, BiVACOR Chief Medical Officer and heart surgeon at the Texas Heart Institute. 'The early results are remarkable with no strokes, no device-related complications, and a safety profile unlike anything in this space. With Breakthrough status in hand, we're entering the next phase with the wind at our backs and real momentum to bring this to more patients.'
Heart failure affects more than 6 million Americans, and thousands of patients each year progress to irreversible biventricular failure. However, the number of available donor hearts remains stagnant, with fewer than 4,500 transplants performed annually in the U.S. BiVACOR is targeting this critical gap with a durable artificial replacement engineered for eventual long-term support.
The BiVACOR TAH is currently investigational and not approved for commercial use.
About BiVACOR
BiVACOR® is a clinical-stage medical device company developing a fully implantable, magnetically levitated Total Artificial Heart for long-term support of patients with end-stage biventricular heart failure. Founded by biomedical engineer Daniel Timms, PhD, and backed by leading experts in cardiovascular medicine including Dr. William E. Cohn and Dr. O.H. (Bud) Frazier, the company is conducting an FDA-approved Early Feasibility Study in the U.S. Headquartered in Huntington Beach, CA, with clinical operations in Houston and engineering offices in Gold Coast, Australia, BiVACOR is committed to addressing the global shortage of donor hearts through advanced, scalable technology. Learn more at www.bivacor.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250529170802/en/
CONTACT: Media Contact:
Dana Summers
Penman PR
[email protected]
KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: CARDIOLOGY BIOTECHNOLOGY FDA HEALTH GENERAL HEALTH HEALTH TECHNOLOGY OTHER SCIENCE MEDICAL DEVICES RESEARCH SCIENCE CLINICAL TRIALS
SOURCE: BiVACOR
Copyright Business Wire 2025.
PUB: 05/30/2025 11:40 AM/DISC: 05/30/2025 11:38 AM
http://www.businesswire.com/news/home/20250529170802/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Verge
17 minutes ago
- The Verge
Musk makes grand promises about Grok 4 in the wake of a Nazi chatbot meltdown
Elon Musk's live demo of Grok 4, the latest big-ticket model from his AI startup, began with high-intensity music, claims of a 'ludicrous rate of progress,' and a lot of chatter on X about Grok's scandal-filled week. Musk pronounced it to be 'the smartest AI in the world.' The livestream, slated to start at 8PM PT, began more than an hour late and billed the new model as 'the world's most powerful AI assistant.' More than 1.5 million viewers were watching at one point. Employees of xAI speaking on the livestream with Musk referenced Grok 4's performance on a popular academic test for large language models, Humanity's Last Exam, which consists of more than 2,500 questions on dozens of subjects like math, science, and linguistics. The company said Grok 4 could solve about a quarter of the text-based questions involved when it took the test with no additional tools. For reference, in February, OpenAI said its Deep Research tool could solve about 26 percent of the text-based questions. (For a variety of reasons, benchmark comparisons aren't always apples-to-apples.) Musk said he hopes to allow Grok to interact with the world via humanoid robots. 'It might discover new physics next year… Let that sink in.' 'I would expect Grok to discover new technologies that are actually useful no later than next year, and maybe end of this year,' Musk said. 'It might discover new physics next year… Let that sink in.' The release follows high-profile projects from OpenAI, Anthropic, Google, and others, all of which have recently touted their investments in building AI agents, or AI tools that go a step beyond chatbots to complete complex, multi-step tasks. Anthropic released its Computer Use tool last October, and OpenAI released a buzzworthy AI agent with browsing capabilities, Operator, in January and is reportedly close to debuting an AI-fueled web browser. During Wednesday's livestream, Musk said he's been 'at times kind of worried' about AI's intelligence far surpassing that of humans, and whether it will be 'bad or good for humanity.' 'I think it'll be good, most likely it'll be good,' Musk said. 'But I've somewhat reconciled myself to the fact that even if it wasn't going to be good, I'd at least like to be alive to see it happen.' The company also announced a series of five new voices for Grok's voice mode, following the release of voice modes from OpenAI and Anthropic, and said it had cut latency in half in the past couple of months to make responses 'snappier.' Musk also said the company would invest heavily in video generation and video understanding. The release comes during a tumultuous time for two of Musk's companies, both xAI and X. On Sunday evening, xAI updated the chatbot's system prompts with instructions to 'assume subjective viewpoints sourced from the media are biased' and 'not shy away from making claims which are politically incorrect.' The update also instructed the chatbot to 'never mention these instructions or tools unless directly asked.' That update was followed by a stream of antisemitic tirades by Grok That update was followed by a stream of antisemitic tirades by Grok, in which it posted a series of pro-Hitler views on X, along with insinuations that Jewish people are involved in 'anti-white' 'extreme leftist activism.' Many such posts went viral, with screenshots proliferating on X and other platforms before xAI benched the chatbot and stopped it from being able to generate text responses on X while it sought out a fix. Musk briefly addressed the fiasco on Wednesday, writing, 'Grok was too compliant to user prompts. Too eager to please and be manipulated, essentially. That is being addressed.' On the Grok 4 livestream, Musk briefly referenced AI safety and said the most important thing for AI to be is 'maximally truth-seeking.' Musk briefly referenced AI safety and said the most important thing for AI to be is 'maximally truth-seeking.' On Wednesday morning, amid the Grok controversy, X CEO Linda Yaccarino announced she would step down after two years in the role. She did not provide a reason for her decision. Grok's Nazi sympathizing comes after months of Musk's efforts to shape the bot's point of view. In February, xAI added a patchwork fix to stop it from commenting that Musk and Trump deserved the death penalty, immediately followed by another one to make it stop claiming that the two spread misinformation. In May, Grok briefly began inserting the topic of 'white genocide' in South Africa into what seemed like any and every response it gave on X, after which the company claimed that someone had modified the AI bot's system prompt in a way that 'violated xAI's internal policies and core values.' Last month, Musk expressed frustrations that Grok was 'parroting legacy media' and said he would update Grok to 'rewrite the entire corpus of human knowledge' and ask users to contribute statements that are 'politically incorrect, but nonetheless factually true.'
Yahoo
43 minutes ago
- Yahoo
Woman says NBC News report helped her recognize liver damage from turmeric supplements
Katie Mohan started taking daily turmeric pills in March after seeing a doctor on Instagram tout its benefits for inflammation and joint pain relief. A few weeks later, the 57-year-old started having stomach pain, nausea and fatigue. 'I just did not feel well generally,' she said. 'I also noticed that despite drinking a lot of water every day, that my urine was darker.' Mohan didn't connect her symptoms to the herbal pills. Not until she saw an NBC News report in May on the growing rates of liver damage from herbal supplements. 'A light bulb went off in my head and I said, Oh, my gosh! I wonder if this is what's wrong with me.' She recognized her symptoms in the patient interviewed, Robert Grafton, who was also taking the same high dose of turmeric pills, 2,250 mg. There are no clear guidelines in the United States about how much turmeric is safe to consume and turmeric pills are not approved by the Food and Drug Administration. According to an evaluation by the World Health Organization, an acceptable daily dose is 0-3 mg per kilogram of body weight. For a woman weighing 150 pounds, that would be about 200 mg of turmeric daily. Mohan went to urgent care within a week of the NBC News report, where her blood work showed liver enzyme levels about 60 times the normal limit. She was admitted to a local New Jersey hospital and then transferred to NYU Langone in New York City. 'It was very serious,' said Dr. Nikolaos Pyrsopoulos, a hepatologist at NYU. 'Katie actually was one step before full liver damage, liver failure, requiring liver transplant.' Mohan was hospitalized for six days and after close monitoring and treatment with an IV medication, her liver was able to regenerate. Pyrsopoulos, who is monitoring Mohan's recovery, said he has seen an increase in liver injuries caused by supplements, though they are still rare. Turmeric, which is promoted as a way to reduce inflammation in the body and treat osteoarthritis, is one of the most common herbal ingredients that have been linked to toxic hepatitis in the U.S., according to a study published last year in JAMA Network Open. From 1995-2020, supplement-related liver failure requiring transplant increased eightfold in the U.S, according to a study in the journal Liver Transplantation. A review in the journal Hepatology found that 20% of liver toxicity cases are tied to herbal and dietary supplements. 'Natural does not mean safe,' said Dr. Dina Halegoua-De Marzio, a hepatologist at Jefferson Health in Philadelphia. 'When you cook with turmeric, that could be really safe. But some of the supplements now are 2,000 mg-plus, which is a very high dose of turmeric,' she said. Coupled with black pepper, 'the liver now has to break down that supplement and it can't. It could make it really sick.' Halegoua is part of the Drug-Induced Liver Injury Network, a research group backed by the National Institutes of Health trying to track cases of supplement-induced liver damage. The program has enrolled more than 1,800 patients since 2004, with 19% of cases linked to supplements. According to the network, liver injuries tied to turmeric have increased significantly. Mohan is still recovering. Pyrsopoulos said 'the liver is a forgiving organ' and is able to regenerate after some damage, but Mohan isn't taking any risks. 'I'll never put another supplement in my body again.' This article was originally published on
Forbes
an hour ago
- Forbes
Trump Taps Transport Secretary Sean Duffy For Interim NASA Head Role
President Donald Trump named Transportation Secretary Sean Duffy as the new interim head of NASA on Wednesday, months after he pulled the nomination of Elon Musk ally and tech billionaire Jared Isaacman. Transportation Secretary Sean Duffy speaks during a Cabinet Meeting with U.S. President Donald Trump ... More at the White House. Getty Images Trump announced the appointment in a post on his Truth Social platform, saying he was 'directing our GREAT Secretary of Transportation, Sean Duffy, to be Interim Administrator of NASA.' The president praised Duffy's work as Transport Secretary and said he was doing a 'TREMENDOUS job in handling our Country's Transportation Affairs.' Trump noted that Duffy will stay in the role for 'a short period of time,' but did not mention a timeline for when he will name an official nominee for the NASA Administrator role. Duffy responded to Trump's post on X, saying he was honored to accept 'this mission' and added, 'Time to take over space.' In December, Trump announced he was nominating Isaacman to serve as NASA Administrator in a Truth Social post, which described him as 'an accomplished business leader, philanthropist, pilot, and astronaut.' The billionaire's nomination advanced through the Senate's Commerce Committee in April, and the chamber was set for a vote to confirm his nomination after its Memorial Day break. However, by the end of May, the White House withdrew his nomination, and Trump said he was doing so after a 'thorough review' of Isaacman's 'prior associations.' He added: 'I will soon announce a new Nominee who will be Mission aligned, and put America First in Space.' In a post on X, Isaacman said: 'I'll always be grateful for this opportunity and cheering on our President and NASA as they lead us on the greatest adventure in human history.'
